Early predictors of the life-threatening complications of inflammatory bowel diseases: the retrospective cohort study results

Introduction. Ulcerative colitis and Crohn’s disease belong to the inflammatory bowel diseases (IBD) and are one of the most urgent problems of gastroenterology worldwide, including due to frequent recurrence and development of specific complications. The aim of the study was to identify predictors of the development of life-threatening complications of IBD. Materials and Methods. A retrospective cohort study was conducted, 250 patients with ulcerative colitis and 266 patients with Crohn’s disease were included, they were observed in the specialized IBD city clinic in St. Petersburg, Russia. Demographic features of the patient’s cohort, clinical characteristics of the disease and the therapy used were assessed. The studied outcome was the development of the chronologically first life-threatening complication in the history of the disease. Data analysis included basic statistical methods, Kaplan-Meier survival analysis and Cox regression. Results. The median duration of patient follow-up from the moment of diagnosis was 2.5 years for ulcerative colitis and 2 years for Crohn’s disease. The incidence of life-threatening complications in ulcerative colitis was 8.0%, in Crohn’s disease - 28.2%. In ulcerative colitis, the predominant life-threatening complication was severe anemia requiring hemotransfusion, whereas in Crohn’s disease, complete intestinal stricture and intestinal perforation were the most common complications as a severe anemia. Only 59% of cases of life-threatening complications of IBD occurred after this diagnosis was established, while in 29% of cases they developed at the disease onset and became the reason for the IBD diagnosis, and in 12% of patients even the development of a life-threatening complication did not become the reason for the IBD diagnosis. As a result of multivariate Cox regression analysis, independent factors (predictors) of the development of life-threatening complications of IBD were identified: in Crohn’s disease, therapy with 5-aminosalicylic acid (5-ASA) and/or corticoids alone (RR 9.4; 95% CI 2.9-30.5) and a continuously recurrent or acute course of the disease (RR 3.0; 95% CI 1.1-8.3), and for ulcerative colitis, 5-ASA monotherapy (RR 28.0; 95% CI 2.0-401.0), a continuously recurrent or acute course of disease (OR 26.2; 95% CI 3.2-215.4), and a history of non-life-threatening complications (RR 7.7; 95% CI 1.5-39.8). Conclusion. To prevent the life-threatening complications development, both timely diagnosis of IBD and active specific therapy aimed at achieving and maintaining long-term remission of the disease are necessary. The presence of the above-mentioned predictors of life-threatening complications of ulcerative colitis and Crohn’s disease can be considered as a basis for intensification of IBD therapy using immunosuppressors, targeted immunosuppressors and biologics, taking into account a personalized approach to therapy of IBD patients.

Ulcerative colitis, Crohn’s disease

1. Ivashkin V.T., Shelygin Yu.A., Belousova E.A. et al. Clinical guidelines. Ulcerative colitis (К51), adults. Coloproctology. 2023;22(1):10-44. (in Russ.) doi: 10.33878/2073-7556-2023-22-1-10-44.@@ Шелыгин Ю.А., Ивашкин В.Т., Белоусова Е.А. и соавт. Клинические рекомендации. Язвенный колит (K51), взрослые. Колопроктология. 2023;22(1):10-44. doi: 10.33878/2073-7556-2023-22-1-10-44.

2. Shelygin Yu.A., Ivashkin V.T., Achkasov S.I. et al. Clinical guidelines. Crohn’s disease (К50), adults. Koloproktologia. 2023;22(3):10-49. (in Russ.) doi: 10.33878/2073-7556-2023-22-3-10-49.@@ Шелыгин Ю.А., Ивашкин В.Т., Ачкасов С.И. и соавт. Клинические рекомендации. Болезнь Крона (К50), взрослые. Колопроктология. 2023;22(3):10-49. doi: 10.33878/2073-7556-2023-22-3-10-49.

3. Raine T., Bonovas S., Burisch J. et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. Journal of Crohn’s and Colitis. 2022:16(1):2-17. doi: 10.1093/ecco-jcc/jjab178.

4. Torres J., Bonovas S., Doherty G. et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. Journal of Crohn’s and Colitis. 2020:14(1):4-22. doi: 10.1093/ecco-jcc/jjz180.

5. Fumery M., Singh S., Dulai P.S. et al. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review. Clin Gastroenterol Hepatol. 2018;16:343-356.e3. doi: 10.1016/j.cgh.2017.06.016.

6. Le Berre C., Danese.S, Peyrin-Biroulet L. Can we change the natural course of inflammatory bowel disease? Therap Adv Gastroenterol. 2023:16:17562848231163118. doi: 10.1177/1756284823116311.

7. Uspenskiy Y.P., Ivanov S.V., Krasichkov A.S. et al. Relationship between undernutrition and anemia in patients with ulcerative colitis. Gastroenterology Insights. 2023;14(1):27-36. doi: 10.3390/gastroent14010003.

8. Uspenskiy Y.P., Ivanov S.V., Fominykh Y.A. et al. Features of the complicated course and extraintestinal manifestations of inflammatory bowel diseases. University Therapeutic Journal. 2023;5(2):68-83. (in Russ.) doi: 10.56871/UTJ.2023.72.18.006.@@ Успенский Ю.П., Иванов С.В., Фоминых Ю.А. и соавт. Особенности осложненного течения и внекишечных проявлений воспалительных заболеваний кишечника. University Therapeutic Journal. 2023;5(2):68-83. doi: 10.56871/UTJ.2023.72.18.006.

9. Peyrin-Biroulet L., Loftus E.V., Colombel J.-F. et al. The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol. 2010; 105:289-297. doi: 10.1038/ajg.2009.579.

10. Zhao M., Lo B.Z.S., Vester-Andersen M.K. et al. A 10-year follow-up study of the natural history of perianal Crohn’s disease in a Danish population-based inception cohort. Inflamm Bowel Dis. 2019;25:1227-1236. doi: 10.1093/ibd/izy374.

11. Fumery M., Pariente B., Sarter H. et al. Natural history of Crohn’s disease in elderly patients diagnosed over the age of 70 years: a population-based study. Inflamm Bowel Dis. 2016; 22: 1698-1707. doi: 10.1097/MIB.0000000000000821.

12. Shi H.Y., Chan F.K.L., Leung W.K. et al. Natural history of elderly-onset ulcerative colitis: results from a territory-wide inflammatory bowel disease registry. J Crohns Colitis. 2016;10:176-185. doi: 10.1093/ecco-jcc/jjv194.

13. Turner D., Ricciuto A., Lewis A. et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570-1583. doi: 10.1053/j.gastro.2020.12.031.

14. Uspenskiy Y.P., Shabrov A.V., Ivanov S.V. et al. Basic therapy for inflammatory bowel diseases in St. Petersburg, Russia: results of a multicenter study. Experimental and clinical gastroenterology. 2022; 198(2):54-76. (in Russ.) doi: 10.31146/1682-8658-ecg-198-2-64-76.@@ Успенский Ю.П., Шабров А.В., Иванов С.В. и соавт. Базисная терапия воспалительных заболеваний кишечника в Санкт-Петербурге: результаты многоцентрового исследования. Экспериментальная и клиническая гастроэнтерология. 2022;198(2):54-76. doi: 10.31146/1682-8658-ecg-198-2-64-76.

15. Petrov S.V., Uspenskiy Y.P., Fominykh Y.A. Clinical case of complicated Crohn’s disease: difficulties of diagnosis and treatment. University Therapeutic Journal. 2022;4(3):39-46. (In Russ.) doi: 10.56871/1531.2022.49.85.005@@ Петров С.В., Успенский Ю.П., Фоминых Ю.А. и соавт. Клинический случай осложненного течения болезни Крона: трудности диагностики и лечения. University Therapeutic Journal. 2022;4(3):39-46. doi: 10.56871/1531.2022.49.85.005.

16. Uspenskiy Y.P., Ivanov S.V., Fominykh Y.A., Narkevich A.N., Segal’ A.M., Grjibovski A.M. Prediction of life-threatening complications of inflammatory bowel disease using neural networks: a practical tool for health care professionals. Experimental and Clinical Gastroenterology. 2023;217(9):20-33. (In Russ.) doi: 10.31146/1682-8658-ecg-217-9-20-33.@@ Успенский Ю.П., Иванов С.В., Фоминых Ю.А., Наркевич А.Н., Сегаль А.М., Гржибовский А.М. Прогнозирование развития жизнеугрожающих осложнений воспалительных заболеваний кишечника с использованием нейронных сетей: инструменты для практического здравоохранения. Экспериментальная и клиническая гастроэнтерология. 2023;217(9):20-33. doi: 10.31146/1682-8658-ecg-217-9-20-33.

17. Uspenskiy Y.P., Petrov S.V., Fominykh Y.A. Clinical features of ulcerative colitis and Crohn’s disease in St. Petersburg: experience of the specialized city clinic for inflammatory bowel diseases treatment. Pharmateca. 2024;1:32-40. (in Russ.) doi: 10.18565/pharmateca.2024.1.32-40.@@ Успенский Ю.П., Петров С.В., Фоминых Ю.А. Клинические особенности язвенного колита и болезни Крона в Санкт-Петербурге: опыт работы городского центра воспалительных заболеваний кишечника. Фарматека. 2024;1:32-40. doi: 10.18565/pharmateca.2024.1.32-40.

18. Uspenskiy Y.P., Ivanov S.V., Fominikh Y.A. et al. Features of inflammatory bowel diseases in St. Petersburg and peculiarities of basic therapy in the regional healthcare system: cross-sectional study results. Experimental and Clinical Gastroenterology. 2021;1(6):29-39. (in Russ.) doi: 10.31146/1682-8658-ecg-190-6-29-39.@@ Успенский Ю.П., Иванов С.В., Фоминых Ю.А. и соавт. Клиническая характеристика воспалительных заболеваний кишечника в Санкт-Петербурге и особенности использования базисной терапии в системе городского здравоохранения: результаты одномоментного эпидемиологического исследования. Экспериментальная и клиническая гастроэнтерология. 2021;190(6):29-39. doi: 10.31146/1682-8658-ecg-190-6-29-39.

19. Uspenskiy Y.P., Ivanov S.V., Fominykh Y.A. et al. Colorectal cancer in inflammatory bowel diseases in St. Petersburg: results of an analytical study. Experimental and Clinical Gastroenterology. 2023;217(9): 138-149. (In Russ.) doi: 10.31146/1682-8658-ecg-217-9-138-149.@@ Успенский Ю.П., Иванов С.В., Фоминых Ю.А. и соавт. Колоректальный рак при воспалительных заболеваниях кишечника в Санкт-Петербурге: результаты аналитического исследования. Экспериментальная и клиническая гастроэнтерология. 2023;217(9): 138-149. doi: 10.31146/1682-8658-ecg-217-9-138-149.

20. Colombel J.F., Narula N., Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology. 2017;152(2):351-361.e5. doi: 10.1053/j.gastro.2016.09.046.